For instance, we have demonstrated that additional “tertiary mutations”, such as PDGFRA and MYCN amplification, promoted patient tumor progression and xenograft formation in IDH1-mutant astrocytoma. The gene discussed is PDGFRA; the disease is astrocytoma (excluding glioblastoma).